Acneiform Rash
Conditions
Keywords
Acneiform eruption, papulopustular, EGFR, cetuximab, erlotinib, gefitinib, panitumumab, eruption secondary to treatment with either cetuximab
Brief summary
The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.
Detailed description
The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.
Interventions
DRUGThreolone ointment
ointment once daily for 1 month
DRUGointment Synthomycine
ointment once daily for 1 month
DRUGAqua cream
ointment once daily for 1 month
Sponsors
Rabin Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who are planed to initiate treatment with either cetuximab , erlotinib, gefitinib or panitumumab.
Exclusion criteria
* Patients who received any facial topical treatment / systemic antibiotics or any anti-inflammatory drug during the 2 weeks prior to study initiation. * Known hypersensitivity to ointment Synthomycine or to Threolone. * Patients presented with cutaneous rash during the 2 weeks prior to study initiation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients developing grade 2 / above rash under preventative treatment with ointment threolone, compared to the other 2 treatment arms. | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients developing a rash under preventative treatment with ointment threolone, compared to the other 2 treatment arms | 3 years |
Countries
Israel
Outcome results
None listed